{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T03:27:42Z","timestamp":1793935662071,"version":"4.8.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>To summarize recent advances in systemic sclerosis (SSc) highlighted at the 2026 World Scleroderma Congress, focusing on early disease, immunovascular mechanisms, and emerging therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Recent data support a paradigm shift in SSc, demonstrating that disease onset occurs during a very early phase (VEDOSS) characterized by early immune activation and microvascular dysfunction. Type I interferon-driven pathways are increasingly implicated in vascular and myocardial involvement, reinforcing the concept of a shared immunovascular axis across organ systems. Advances in multimodal imaging and circulating biomarkers enable detection of subclinical organ disease, while multi-omic and data-driven approaches are redefining disease subsets beyond traditional classifications. In parallel, novel therapeutic strategies \u2013 including targeted immune modulation, autologous haematopoietic stem cell transplantation (AHSCT), and emerging CAR-T approaches \u2013 are driving a transition toward earlier, mechanism-based intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Systemic sclerosis is increasingly understood as a dynamic continuum of autoimmune\/inflammatory and fibrotic mechanisms that can be identified through imaging, biohumoral, and functional insights, thus enabling a very early\/early diagnosis, a risk stratification, and a precision-based therapeutic approach.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000001204","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:00:40Z","timestamp":1792414840000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Systemic sclerosis in 2026: emerging paradigms from the World Scleroderma Congress"],"prefix":"10.1097","author":[{"given":"Cristiana","family":"Sieiro Santos","sequence":"first","affiliation":[{"name":"Centre for Musculoskeletal Research, The University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Allanore","sequence":"additional","affiliation":[{"name":"Rheumatology department, Universit\u00e9 Paris Cit\u00e9, Saint Joseph Hospital, INSERM U1016, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Matucci-Cerinic","sequence":"additional","affiliation":[{"name":"Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University"},{"name":"Vita-Salute San Raffaele University, Milan, Italy"},{"name":"Inflammation Fibrosis and Ageing Initiative, (INFLAGE), Division of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,11,6]]},"reference":[{"key":"R1-20261106","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an ACR\/EULAR collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R2-20261106","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"R3-20261106","doi-asserted-by":"crossref","first-page":"e834","DOI":"10.1016\/S2665-9913(21)00244-7","article-title":"Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the EUSTAR VEDOSS cohort","volume":"3","author":"Bellando-Randone","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"R4-20261106","first-page":"123","article-title":"Very early diagnosis of systemic sclerosis: new perspectives","volume":"36","author":"Lescoat","year":"2024","journal-title":"Curr Opin Rheumatol"},{"issue":"(Suppl 1)","key":"R5-20261106","article-title":"Abstract book. 9th World Scleroderma Congress","year":"2026","journal-title":"J Scleroderma Relat Disord"},{"key":"R6-20261106","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/ard-2024-226430","article-title":"EULAR recommendations for the treatment of systemic sclerosis: 2023 update","volume":"84","author":"Del Galdo","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R7-20261106","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/ard-2024-226429","article-title":"Results from the international collaborative systematic literature review informing the 2023 EULAR recommendations for the treatment of systemic sclerosis","volume":"84","author":"Lescoat","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R8-20261106","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/art.43120","article-title":"Serum type I interferon score for prediction of clinically meaningful disease progression in limited cutaneous systemic sclerosis","volume":"77","author":"Di Donato","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"R9-20261106","doi-asserted-by":"crossref","first-page":"2402533","DOI":"10.1183\/13993003.02533-2024","article-title":"ERS\/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease","volume":"67","author":"Antoniou","year":"2026","journal-title":"Eur Respir J"},{"key":"R10-20261106","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/BOR.0000000000000965","article-title":"Raynaud phenomenon and microvasculopathy in systemic sclerosis: multimodality imaging for diagnosis and evaluation","volume":"35","author":"Markousis-Mavrogenis","year":"2023","journal-title":"Curr Opin Rheumatol"},{"key":"R11-20261106","doi-asserted-by":"crossref","first-page":"152126","DOI":"10.1016\/j.semarthrit.2022.152126","article-title":"Cardiac inflammation and fibrosis patterns in systemic sclerosis evaluated by magnetic resonance imaging: an update","volume":"58","author":"Mavrogeni","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"R12-20261106","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/ehjci\/jeac094","article-title":"Diffuse myocardial fibrosis precedes subclinical functional myocardial impairment and provides prognostic information in systemic sclerosis","volume":"24","author":"Gotschy","year":"2023","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"R13-20261106","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/23971983241313096","article-title":"Cardiac involvement in systemic sclerosis: a critical review of knowledge gaps and opportunities","volume":"10","author":"Jones","year":"2025","journal-title":"J Scleroderma Relat Disord"},{"key":"R14-20261106","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.semarthrit.2017.03.020","article-title":"Cardiovascular magnetic resonance in systemic sclerosis: pearls and pitfalls","volume":"47","author":"Mavrogeni","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"R15-20261106","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis\u2013associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"R16-20261106","first-page":"2555","article-title":"Mycophenolate versus cyclophosphamide in systemic sclerosis-associated interstitial lung disease (SLS II)","volume":"374","author":"Tashkin","year":"2016","journal-title":"N Engl J Med"},{"key":"R17-20261106","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: focuSSced trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"R18-20261106","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/BOR.0000000000000899","article-title":"Treatment of systemic sclerosis-associated interstitial lung disease: current approaches and future directions","volume":"34","author":"Volkmann","year":"2022","journal-title":"Curr Opin Rheumatol"},{"key":"R19-20261106","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/art.70043","article-title":"Impact of evolving treatment patterns on interstitial lung disease progression in systemic sclerosis using the EUSTAR database","volume":"78","author":"Campochiaro","year":"2026","journal-title":"Arthritis Rheumatol"},{"key":"R20-20261106","first-page":"103500","article-title":"Gastrointestinal manifestations of systemic sclerosis","volume":"24","author":"Alcal\u00e1-Gonz\u00e1lez","year":"2025","journal-title":"Autoimmun Rev"},{"issue":"(Suppl 3)","key":"R21-20261106","doi-asserted-by":"crossref","first-page":"S173","DOI":"10.5152\/eurjrheum.2020.19192","article-title":"Molecular \u201comic\u201d signatures in systemic sclerosis","volume":"7","author":"Mehta","year":"2020","journal-title":"Eur J Rheumatol"},{"key":"R22-20261106","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.ard.2025.04.025","article-title":"Spatial multiomics decipher fibroblast-macrophage dynamics in systemic sclerosis","volume":"84","author":"Li","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"(Suppl 1)","key":"R23-20261106","first-page":"135","article-title":"Genetic susceptibility to interstitial lung disease associated with systemic sclerosis","volume":"9","author":"Tochimoto","year":"2016","journal-title":"Clin Med Insights Circ Respir Pulm Med"},{"key":"R24-20261106","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/S2665-9913(24)00282-0","article-title":"CD19 CAR T-cell therapy in diffuse systemic sclerosis: a case series","volume":"7","author":"Auth","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"R25-20261106","doi-asserted-by":"crossref","first-page":"114071","DOI":"10.1016\/j.ejca.2024.114071","article-title":"Application of blinatumomab in severe systemic sclerosis: a case study","volume":"204","author":"Subklewe","year":"2024","journal-title":"Eur J Cancer"},{"key":"R26-20261106","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/1744666X.2024.2402494","article-title":"Innovative cell therapies for systemic sclerosis: available evidence and new perspectives","volume":"21","author":"Lescoat","year":"2025","journal-title":"Expert Rev Clin Immunol"},{"key":"R27-20261106","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40259-024-00692-z","article-title":"CAR T-cell therapy for rheumatic diseases: what does the future hold?","volume":"39","author":"Avouac","year":"2025","journal-title":"BioDrugs"},{"key":"R28-20261106","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152638","article-title":"Management of disease progression after autologous hematopoietic stem cell transplantation in systemic sclerosis","volume":"71","author":"Spierings","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"R29-20261106","doi-asserted-by":"crossref","first-page":"e005776","DOI":"10.1136\/rmdopen-2025-005776","article-title":"New horizons in systemic sclerosis treatment: advances and emerging therapies in","volume":"11","author":"Sieiro Santos","year":"2025","journal-title":"RMD Open"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0000000000001204","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T03:01:56Z","timestamp":1793934116000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0000000000001204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11,6]]},"references-count":29,"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001204","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,11,6]]}}}